Monoamine oxidase inhibitors in neurological diseases
By: edited by Abraham Lieberman ... [et al.].
Contributors: Lieberman, A. N. 1938-
Series: Neurological disease and therapy ;; 21; Neurological disease and the therapy ;; v. 21
Publisher: M. Dekker
Published: 1994
Place of publication: New York
Language: eng
Number of pages: 371
Subjects: Monoamine oxidase -- Inhibitors -- Therapeutic use.; Nervous system -- Degeration -- Chemotherapy.; Monoamine oxidase.; Selegiline -- Therapeutic use.; Parkinson's disease -- Chemotherapy.; Monoamine Oxidase -- metabolism.; Monoamine Oxidase Inhibitors -- therapeutic use.; Parkinson Disease -- etiology.; Parkinson Disease -- drug therapy.
Description: "Emphasizing the role of monoamine oxidase (MAO) in the etiology and pathogenesis of Parkinson's disease and Alzheimer's disease, this up-to-date reference describes the genetics, physiology, biochemistry, pharmacology, and clinical aspects of this very important class of enzymes. Details how the interaction between selegiline (deprenyl) and MAO may retard the progression of neurodegenerative disorders! Providing the latest theories on how selegiline operates, Monoamine Oxidase Inhibitors in Neurological Diseases - presents fundamental information on MAO types A and B - examines the distribution of MAO A and B in the normal human brain - investigates the effects of disease and aging on MAO A and B - analyzes a critical role for MAO in the toxic action in Parkinson's disease - elucidates selegiline's novel ability to delay the progression or repair the damage of dopaminergic neurons - discusses the usefulness of MAO inhibitors in psychiatric disease - and more!!"--Publisher description (LoC).
Notes: Includes bibliographical references and index.